Johnson & Johnson (United Kingdom)

Recent papers from Johnson & Johnson (United Kingdom)

1. The Accumulation of Healthcare, Benefit and Social Care Costs of Depression Before and After Diagnosis: A Six-Year Observational Cohort StudyPharmacoEconomics · 2026
2. Modeling Long-Term Progression-Free Survival in Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Bortezomib, Lenalidomide, and DexamethasoneJournal of Clinical Oncology · 2026
3. Understanding underserved and underrepresented populations in European clinical studies: a narrative review with systematic approachTrials · 2026
4. Improving Patient Access to New Treatment Modalities in European Cancer CareJournal of Market Access & Health Policy · 2026
5. Full enrollment results from cohort 1 of the phase III randomized THOR trial of erdafitinib versus chemotherapy in FGFR-altered advanced urothelial carcinomaESMO Open · 2026
6. Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Transplant-Ineligible Subgroup Analysis of CEPHEUSJournal of Clinical Oncology · 2026
7. Treatment patterns, intensive treatment, and hospitalization-related burden of juvenile generalized myasthenia gravis in Japan: a retrospective cohort study using a hospital-based claims databaseFrontiers in Neurology · 2026
8. Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 studyClinical Cancer Research · 2026
9. A transient multiscale framework for elastohydrodynamic lubrication of rough ball-in-socket bearingsComputer Methods in Applied Mechanics and Engineering · 2026
10. Secondary use and scholarly impact of a portfolio of clinical trials with shared individual participant level data: cross sectional studyBMJ · 2026
11. Clinical features and management of GPRC5D-associated adverse events in novel GPRC5D × CD3 bispecific talquetamab-treated relapsed/refractory multiple myeloma patients: the MonumenTAL-1 China cohort experienceHematology · 2026
12. A Prospective, Multi-Center, Randomized Controlled Study to Evaluate the Efficacy and Safety of Two Absorbable Barbed Sutures in Thyroid SurgeryMedical Devices Evidence and Research · 2026
13. siRNA daplusiran/tomligisiran and DNA vaccine JNJ-64300535 in NA-suppressed chronic hepatitis B: the OSPREY studynpj Vaccines · 2026
14. Daratumumab plus bortezomib, lenalidomide, and dexamethasone in transplant-deferred newly diagnosed multiple myeloma: Frailty subgroup analysis of CEPHEUSLeukemia · 2026
15. Efficacy and Safety of Teclistamab in Relapsed/Refractory Multiple Myeloma: 2‐Year Follow‐Up From MajesTEC‐1 China CohorteJHaem · 2026
16. A Decade of the YODA Project: Advancing Clinical Trial Data Sharing through Transparency, Independence, and CollaborationScientific Data · 2026
17. Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn’s disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 yearsIntestinal Research · 2026
18. Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancerEuropean Journal of Cancer · 2026
19. Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trialNature Medicine · 2026
20. New Modalities and Carcinogenicity AssessmentToxicologic Pathology · 2026